StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)
October 16, 2024 6:02 AM
Goldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $369.00 price target on Amgen (NASDAQ: AMGN).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
October 15, 2024 2:20 PM
Amgen (AMGN) presents positive top-line results from the Phase 3 MINT trial
October 15, 2024 8:01 AM
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
October 15, 2024 8:00 AM
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.47%
October 14, 2024 5:02 PM
Truist Securities Downgrades Amgen (AMGN) to Hold
October 14, 2024 6:05 AM
